BioPharma Dive December 12, 2022
The company is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
Sometime in the next few weeks, a person living with the inherited blood disease beta thalassemia will have their stem cells collected as the first step to receive a newly approved gene therapy for their condition.
Cleared by the Food and Drug Administration in August, the gene therapy is made by Bluebird bio, a Massachusetts-based drugmaker that’s spent the past decade developing the personalized treatment. Its approval was a milestone for the company and the gene therapy field, as well as for the hundreds of people in the U.S. who have a severe...
Today's Sponsors
Today's Sponsor